Merck KGaA to acquire Silence Therapeutics for about $1.3 billion
Merck KGaA said it will acquire Silence Therapeutics in an all-cash deal valued at about $1.3 billion.
By 1330 GMT on Monday, German drugmaker Merck KGaA said it will buy Silence Therapeutics in an all-cash transaction valued at about $1.3 billion. The acquisition would add precision-engineered medicines and gene silencing to Merck KGaA’s portfolio.